Empagliflozin tied to meaningful reduction of HbA1c compared to linagliptin in young diabetes patients: Lancet Jacinthlyn Sylvia9 March 2023 11:15 AM ISTA new study published in The Lancet Diabetes & Endocrinology suggests that linagliptin did not reduce HbA1c in a clinically meaningful way,...
SGLT2 inhibitor empagliflozin could be new treatment option for children with type 2 diabetes: Lancet Dr. Kamal Kant Kohli4 March 2023 11:00 AM ISTUSA: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, findings from a phase 3 clinical trial have...
Medical Bulletin 25/February/2023 Isra Zaman25 Feb 2023 2:45 PM ISTHere are the top medical news for the day: Oral empagliflozin provided safe glycemic control in children with type 2 diabetes: Phase 3 trial...
Oral empagliflozin provided safe glycemic control in children with type 2 diabetes: Phase 3 trial findings Isra Zaman25 Feb 2023 9:00 AM ISTResearchers led by pediatric endocrinologists at Joslin Diabetes Center recently completed a phase 3 clinical trial that assessed the efficacy and...
Empagliflozin promising in hyponatremia induced by Chronic Syndrome of Inappropriate Antidiuresis Dr Kartikeya Kohli10 Feb 2023 11:30 AM ISTSwitzerland: According to clinical research on acid-base and electrolyte disorders, the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
USFDA accepts supplemental New Drug Application for Jardiance for adults with chronic kidney disease: Eli Lilly Ruchika Sharma22 Jan 2023 12:00 PM ISTIndianapolis: The U.S. Food and Drug Administration (USFDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin)...
Torrent Pharma collaborates with Boehringer Ingelheim India to co-market its anti-diabetic drug, its fixed dose combinations in India Ruchika Sharma14 Dec 2022 4:50 PM ISTAhmedabad: Torrent Pharmaceuticals Ltd has entered into a strategic alliance with Boehringer Ingelheim India Private Limited to co-market Cospiaq...
Empagliflozin improves outcomes in HF with preserved EF irrespective of BP: the EMPEROR-Preserved trial Medha Baranwal13 Dec 2022 10:30 AM ISTGermany: Empagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular (CV) death in HRpEF (heart failure and preserved...
Empagliflozin as add-on therapy improves quality of life in diabetes patients Medha Baranwal28 Nov 2022 10:15 AM ISTPunjab: Empagliflozin can be recommended as an add-on medication in type 2 diabetes (T2D) patients with hypertension with regards to improving their...
Empagliflozin reduces risk of disease progression and death in high-risk CKD patients: NEJM Medha Baranwal7 Nov 2022 10:30 AM ISTUK: Empagliflozin therapy in patients with chronic kidney disease (CKD) lowers the risk of disease progression or death from cardiovascular causes in...
Dual or single SGLT inhibition: which is more beneficial for type 2 diabetes? Study sheds light Medha Baranwal19 Oct 2022 9:30 AM ISTIn type 2 diabetes patients, the study did not indicate different clinical impacts of dual and single SGLT inhibition.Germany: Inhibition of...
Empagliflozin proves beneficial in acute myocardial infarction: EMMY trial Dr. Kamal Kant Kohli11 Sept 2022 7:30 PM ISTAUSTRIA: Acute myocardial infarction (MI) patients who receive the SGLT2 inhibitor empagliflozin (Jardiance) early after the MI have improved markers...
